Authors: MCLAUGHLIN P GRILLOLOPEZ AJ LINK BK LEVY R CZUCZMAN MS WILLIAMS ME HEYMAN MR BENCEBRUCKLER I WHITE CA CABANILLAS F JAIN V HO AD LISTER J WEY K SHEN D DALLAIRE BK

Citation: P. Mclaughlin et al., RITUXIMAB CHIMERIC ANTI-CD20 MONOCLONAL-ANTIBODY THERAPY FOR RELAPSEDINDOLENT LYMPHOMA - HALF OF PATIENTS RESPOND TO A 4-DOSE TREATMENT PROGRAM, Journal of clinical oncology, 16(8), 1998, pp. 2825-2833

Authors: HENLEY CM WEY K TAKASHIMA A MILLS C GRANMAYEH E KRISHNAPPA I ROBERTSON CS

Citation: Cm. Henley et al., S-ADENOSYLMETHIONINE DECARBOXYLASE ACTIVITY IS DECREASED IN THE RAT CORTEX AFTER TRAUMATIC BRAIN INJURY, Journal of neurochemistry, 69(1), 1997, pp. 259-265

Authors: MALONEY DG GRILLOLOPEZ AJ WHITE CA BODKIN D SCHILDER RJ NEIDHART JA JANAKIRAMAN N FOON KA LILES TM DALLAIRE BK WEY K ROYSTON I DAVIS T LEVY R

Citation: Dg. Maloney et al., IDEC-C2B8 (RITUXIMAB) ANTI-CD20 MONOCLONAL-ANTIBODY THERAPY IN PATIENTS WITH RELAPSED LOW-GRADE NON-HODGKINS-LYMPHOMA, Blood, 90(6), 1997, pp. 2188-2195

Authors: SOLINGER A PAXTON H WEY K YOCUM D

Citation: A. Solinger et al., IMMUNOLOGICAL MARKERS OF RESPONSE IN A MULTIDOSE PROTOCOL-7002 USING AN IMMUNOMODULATING, NON-DEPLETING PRIMATIZED(TM) ANTI-CD4 MONOCLONAL-ANTIBODY IN RHEUMATOID-ARTHRITIS (RA), The FASEB journal, 10(3), 1996, pp. 2552-2552

Authors: MCLAUGHLIN P CABANILLAS F GRILLOLOPEZ AJ LINK GL LEVY R CRUCZMAN M HEYMAN MR WILLIAMS M JAIN V BENCEBRUCKLER L HO AD LISTER J WEY K SHUEY S PARKER E

Citation: P. Mclaughlin et al., PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE ANTI-CD20 ANTIBODY (MAB) IDEC-C2B8 IN PATIENTS (PTS) WITH RELAPSED LOW-GRADE OR FOLLICULAR LYMPHOMA (LG F NHL)/, Blood, 88(10), 1996, pp. 350-350